Challenges in anti-infective therapy for skin conditions: part 2

References

• Heukelbach J, Feldmeier H. Ectoparasites – the underestimated realm. Lancet13, 889–891 (2004).
   Google Scholar
• Chambliss ML. Treating asymptomatic bodily contacts of patients with scabies. Arch. Fam. Med.9, 473–474 (2000).
   PubMedGoogle Scholar
• Kissmeyer A. Rapid ambulatory treatment of scabies with benzyl benzoate lotion. Lancet21 (1937).
   Google Scholar
• Franz TJ, Lehman PA, Franz SF, Guin JD, Comparative percutaneous absorption of lindane and permethrin. Arch. Dermatol.132, 901–905 (1996).
   PubMed Web of Science ®Google Scholar
• Bhalla M, Thami GP. Reversible neurotoxicity after an overdose of topical lindane in an infant. Pediatr. Dermatol.21(5), 597–599 (2004).
   PubMed Web of Science ®Google Scholar
• Solomon LM, Fahrner L, West DP. γ-benzene hexachloride toxicity: a review. Arch. Dermatol.113, 353–357 (1977).
   PubMedGoogle Scholar
• Davies JE, Dedhia HV, Morgade C, Barquet A, Maibach HI. Lindane poisonings. Arch. Dermatol.119, 142–144 (1983).
   PubMed Web of Science ®Google Scholar
• CDC. Unintentional topical lindane ingestions – United States, 1998–2003. MMWR Morb. Mortal. Wkly Rep.54, 533–535 (2005).
   PubMedGoogle Scholar
• Roos TC, Alam M, Roos S, Merk HF, Bickers DR. Pharmacotherapy of ectoparasitic infections. Drugs61, 1067–1088 (2001).
   PubMedGoogle Scholar
• Purvis RS, Tyring SK. An outbreak of lindane-resistant scabies treated successfully with permethrin 5% cream. J. Am. Acad. Dermatol.25, 1015–1016 (1991).
   PubMedGoogle Scholar
• Judd LE. γ-benzene hexachloride resistant scabies. NZ Med. J.106, 61–63 (1993).
   PubMedGoogle Scholar
• Labeling changes for lindane. FDA Consum.37, 6 (2003).
   Google Scholar
• Burgess IF. Sarcoptes scabiei and scabies. Adv. Parasitol.33, 235–292 (1994).
   PubMed Web of Science ®Google Scholar
• Quarterman MJ, Lesher JL. Neonatal scabies treated with permethrin 5% cream. Pediatr. Dermatol.11, 264–266 (1994).
   PubMedGoogle Scholar
• Karthikeyan K. Treatment of scabies: newer perspectives. Postgrad. Med. J.81, 7–11 (2005).
   PubMedGoogle Scholar
• Buffet M, Dupin N. Current treatments for scabies. Fundam. Clin. Pharmacol.17, 217–225 (2003).
   PubMed Web of Science ®Google Scholar
• Burkhart KM, Burkhart CN, Burkhart CG. Our scabies treatment is archaic, but ivermectin has arrived. Int. J. Dermatol.37, 76–77 (1998).
   PubMed Web of Science ®Google Scholar
• Richard-Lenoble D, Chandenier J, Gaxotte P. Ivermectin and filariasis. Fundam. Clin. Pharmacol.17, 199–103 (2003).
   PubMedGoogle Scholar
• del Giudice P, Chosidow O, Caumes E. Ivermectin in dermatology. J. Drugs Dermatol.2, 13–21 (2003).
   PubMedGoogle Scholar
• Madan V, Jaskiran K, Gupta U, Gupta DK. Oral ivermectin in scabies patients: a comparison with 1% topical lindane lotion. J. Dermatol.28, 481–484 (2001).
   PubMedGoogle Scholar
• Chouela EN, Abeldano AM, Pellerano G et al. Equivalent therapeutic efficacy and safety of ivermectin and lindane in the treatment of human scabies. Arch. Dermatol.135, 651–655 (1999).
   PubMedGoogle Scholar
• Glaziou P, Cartel JL, Alzieu P, Briot C, Moulia-Pelat JP, Martin PM. Comparison of ivermectin and benzyl benzoate for treatment of scabies. Trop. Med. Parasitol.44, 331–332 (1993).
   PubMedGoogle Scholar
• Nnoruka EN, Agu CE. Successful treatment of scabies with oral ivermectin in Nigeria. Trop. Doct.31, 15–18 (2001).
   PubMed Web of Science ®Google Scholar
• Brooks PA, Grace RF. Ivermectin is better than benzyl benzoate for childhood scabies in developing countries. J. Paediatr. Child Health.38, 401–404 (2002).
   PubMedGoogle Scholar
• Usha V, Gopalakrishnan Nair TV. A comparative study of oral ivermectin and topical permethrin cream in the treatment of scabies. J. Am. Acad. Dermatol.42, 236–240 (2000).
   PubMed Web of Science ®Google Scholar
• Leppard B, Naburi AE. The use of ivermectin in controlling an outbreak of scabies in a prison. Br. J. Dermatol.143, 520–523 (2000).
   PubMed Web of Science ®Google Scholar
• Millership S, Readman R, Bracebridge S. Use of ivermectin, given orally, to control scabies in homes for the elderly mentally ill. Commun. Dis. Public Health5, 144–116 (2002).
   PubMedGoogle Scholar
• Patel A, Hogan P, Walder B. Crusted scabies in two immunocompromised children: successful treatment with oral ivermectin. Australas. J. Dermatol.40, 37–40 (1999).
   PubMedGoogle Scholar
• Currie BJ, Harumal P, McKinnon M, Walton SF. First documentation of in vivo and in vitro ivermectin resistance in Sarcoptes scabiei. Clin. Infect. Dis.39, e8–e12 (2004).
   Web of Science ®Google Scholar
• Heukelbach J, de Oliveira FA, Feldmeier H. [Ectoparasitoses and public health: challenges for control]. Cad. Saude Publica19, 1535–1540 (2003).
   PubMedGoogle Scholar
• Bezold G, Lange M, Schiener R et al. Hidden scabies: diagnosis by polymerase chain reaction. Br. J. Dermatol.144, 614–618 (2001).
   PubMedGoogle Scholar
• Heukelbach J, Costa ALM, Wilcke T, Mencke N, Feldmeier H. The animal reservoir of Tunga penetrans in poor communities in Northeast Brazil. Med. Vet. Entomol. (2008) (In press).
   PubMedGoogle Scholar
• Heukelbach J, Feldmeier H. Scabies. Lancet367(9524), 1767–1774 (2006).
   PubMed Web of Science ®Google Scholar
• Meinking TL, Clineschmidt CM, Chen C et al. An observer-blinded study of 1% permethrin creme rinse with and without adjunctive combing in patients with head lice. J. Pediatr.141, 665–670 (2002).
   PubMedGoogle Scholar
• Maryanna C, Poorten T, Prose NS. The return of the common bedbug. Pediatr. Dermatol.22(3), 183–187 (2005).
   PubMedGoogle Scholar
• Krueger L. Don’t get bitten by the resurgence of bed bugs. Pest Control.68, 58–64 (2000).
   Google Scholar
• Paul J, Bates J. Is infestation with the common bedbug increasing? BMJ320, 1141 (2000).
   PubMedGoogle Scholar
• George R. A British record of Cimex lectularius. Entomol. Gaz.39, 140 (1998).
   Google Scholar
• Kettle DS. Medical and Veterinary Entomology (2nd Edition). University Press, Cambridge, UK (1995).
   Google Scholar
• Whitson M, Harlan H, Koehler P et al. Bedbugs do bite, and they’re back with a vengeance. UniSci (2001).
   Google Scholar
• Grevelink SA, Lerner EA. Leishmaniasis. J. Am. Acad. Dermatol.34, 257 (1996).
   PubMed Web of Science ®Google Scholar
• Weina PJ, Neafie RC, Wortmann G, Polhemus M, Aronson NE. Old world leishmaniasis: an emerging infection among deployed US military and civilian workers. Clin. Infect. Dis.39, 1674–1680 (2004).
   PubMed Web of Science ®Google Scholar
• Dowlati Y. Cutaneous leishmaniasis: clinical aspect. Clin. Dermatol.14, 425 (1996).
   PubMed Web of Science ®Google Scholar
• Gillis D, Klaus S, Schnur LF et al. Diffusely disseminated cutaneous Leishmania major infection in a child with acquired immunodeficiency. Pediatr. Infect. Dis. J.14(3), 247–249 (1995).
   PubMed Web of Science ®Google Scholar
• Schwartz E, Hatz C, Blum J. New world cutaneous leishmaniasis in travellers. Lancet Infect. Dis.6, 342–349 (2006).
   PubMed Web of Science ®Google Scholar
• Harris E, Kropp G, Belli A, Rodriguez B, Agabian N. Single-step multiplex PCR assay for characterization of new world Leishmania complexes. J. Clin. Microbiol.36, 1989–1995 (1998).
   PubMed Web of Science ®Google Scholar
• Herwaldt BL. Leishmaniasis. Lancet354, 1191–1199 (1999).
   PubMed Web of Science ®Google Scholar
• Vetter RS, Visscher PK. Bites and stings of medically important venomous arthropods. Int. J. Dermatol.37, 481 (1998).
   PubMed Web of Science ®Google Scholar
• Tanenbaum M. Skin and tissue techniques. In: Oculoplastic Surgery (3rd Edition). McCord CD Jr, Tanenbaum M, Nunery WR (Eds). Butterworth-Heinemann, PA, USA 3–4 (1995).
   Google Scholar
• Costerton JW. Cystic fibrosis pathogenesis and the role of biofilms in persistent infection. Trends Microbiol.9(2), 50–52 (2001).
   PubMed Web of Science ®Google Scholar
• Usher LR, Lawson RA, Geary I et al. Induction of neutrophil apoptosis by Pseudomonas aeruginosa exotoxin pyocyanin; a potential mechanism of persistent infection. J. Immunol.168(4), 1861–1868 (2002).
   PubMed Web of Science ®Google Scholar
• Athanasopoulos AN, Economopoulos M, Orlova V et al. The extracellular adherence protein (EAP) of Staphylococcus aureus inhibits wound healing by interfering with host defense and repair mechanisms. Blood107(7), 2720–2727 (2006).
   PubMed Web of Science ®Google Scholar
• Haggar A, Ehrnfelt C, Holgersson J. The extracellular adherence protein from Staphylococcus aureus inhibits neutrophil binding to endothelial cells. Infect. Immun.72(10), 6164–6167 (2004).
   PubMedGoogle Scholar
• Chavakis T, Hussain M, Kanse SM et al. Staphylococcus aureus extracellular adherence protein serves as anti-inflammatory factor by inhibiting the recruitment of host leukocytes. Nat. Med.8(7), 687–693 (2002).
   PubMed Web of Science ®Google Scholar
• Save DE. Recurring and antimicrobial-resistant infections: considering the potential of biofilms in clinical practice. Ostomy Wound Manage.53(4), 46–48 (2007).
   Google Scholar
• Robson MC. Wound Infection. A failure of wound healing caused by an imbalance of bacteria. Surg. Clin. North Am.77(3), 637–650 (1997).
   PubMed Web of Science ®Google Scholar
• Sibbald RG, Browne AC, Coutts P, Queen D. Screening evaluation of an ionized nanocrystalline silver dressing in chronic wound care. Ostomy Wound Manage.47(10), 38–42 (2001).
   PubMedGoogle Scholar
• Ayton M. Wounds that won’t heal. Nurs. Times81(46 Suppl.), S16–S19 (1985).
   Google Scholar
• Davis E. Don’t deny the chance to heal! Presented at: 2nd Joint Meeting of the Wound Healing Society and the European Tissue Repair Society. Boston, MA, USA, 15–19 May, 1996.
   Google Scholar
• Moore K. The cell biology of chronic wounds: the role of inflammation. J. Wound Care8(7), 345–352 (1999).
   PubMedGoogle Scholar
• Page KR, Scott AL, Manabe YC. The expanding realm of heterologous immunity: friend or foe? Cell. Microbiol.8(2), 185–196 (2006).
   PubMed Web of Science ®Google Scholar
• Abd-El-Aleem SA, Morgan C, Ferguson MW et al. Spatial distribution of mast cells in chronic venous leg ulcers. Eur. J. Histochem.49(3), 265–272 (2005).
   PubMedGoogle Scholar
• Gardner SE, Frantz RA, Doebbeling BN. The validity of the clinical signs and symptoms used to identify localized chronic wound infection. Wound Repair Regen.32(4), 200–204 (2001).
   Google Scholar
• Newman LG, Waller J, Palestro CJ et al. Unsuspected osteomyelitis in diabetic foot ulcers. Diagnosis and monitoring by leukocyte scanning with indium in 111 oxyquinoline. JAMA266(9), 1246–1251 (1991).
   PubMed Web of Science ®Google Scholar
• McGuckin M, Goldman R, Bolton L, Salcido R. The clinical relevance of microbiology in acute and chronic wounds. Adv. Skin Wound Care16, 12–23 (2003).
   PubMedGoogle Scholar
• Rochon-Edouard S, Pons JL, Veber B et al. Comparative in vitro and in vivo study of nine alcohol-based handrubs. Am. J. Infect. Control32(4), 200–204 (2004).
   PubMedGoogle Scholar
• Vasquez JA. The emerging problem of infectious diseases: the impact of antimicrobial resistance in wound care. Contemporary issues in wound infection: managing the risks, treating the problem. Wound (Suppl.) 1–9 (2006).
   Google Scholar
• Charles CA, Falabella AF, Fernández-Obregón AC. Leg ulcer management (Chapter 46). In: Surgery of the Skin: Procedural Dermatology. Robinson JK, Hanke CW, Sengelmann RD, Siegel DM (Eds). Elsevier Mosby, London, UK 743–766 (2005).
   Google Scholar
• Curtis C, Patkar N, Xie A et al. Risk of serious bacterial infections among rheumatoid arthritis patients exposed to tumor necrosis factor-α antagonists. Arthritis Rheum.56(4), 1125–1133 (2007).
   PubMed Web of Science ®Google Scholar
• Furst DE, Wallis R, Broder M, Beenhouwer DO. Tumor necrosis factor antagonists: different kinetics and/or mechanisms of action may explain diffrences in the risk for developing granulomatous infection. Semin. Arthritis Rheum.36(3), 159–167 (2006).
   PubMed Web of Science ®Google Scholar
• Roach DR, Bean AG, Demangel C, France MP, Briscoe H, Britton WJ. TNF regulates chemokine induction essential for cell recruitment, granuloma formation, and clearance of mycobacterial infection. J. Immunol.168, 4620–4627 (2002).
   PubMed Web of Science ®Google Scholar
• Schiff MH, Burmester GR, Pangan AL, Kupper H, Spencer-Green JT. Safety of adalimumab (Humira) in global clinical trials of patients with early vs long-standing rheumatoid arthritis (RA). Presented at: The Annual European Congress of Rheumatology (EULAR). Vienna, Austria, 8–11 June, 2005.
   Google Scholar
• Keane J, Gershon S, Wise RP et al. Tuberculosis associated with infliximab, a tumor necrosis factor-α-neutralizing agent. N. Engl. J. Med.345, 1098–1104 (2001).
   PubMed Web of Science ®Google Scholar
• Nunez Martinez O, Ripoll Noiseux C, Carneros Martin JA, Gonzalez Lara V, Gregorio Maranon HG. Reactivation tuberculosis in a patient with anti-TNF-α treatment. Am. J. Gastroenterol.96, 1665–1666 (2001).
   PubMed Web of Science ®Google Scholar
• Liberopoulos EN, Drosos AA, Elisaf MS. Exacerbation of tuberculosis enteritis after treatment with infliximab. Am. J. Med113, 615 (2002).
   PubMed Web of Science ®Google Scholar
• Lee JH, Slifman NR, Gershon SK et al. Life-threatening histoplasmosis complicating immunotherapy with tumor necrosis factor-α antagonists infliximab and etanercept. Arthritis Rheum.46(10), 2565–2570 (2002).
   PubMed Web of Science ®Google Scholar
• Nakelchik M, Mangino JE. Reactivation of histoplasmosis after treatment with infliximab. Am. J. Med.112, 78 (2002).
   PubMed Web of Science ®Google Scholar
• True DG, Penmetcha M, Peckham SJ. Disseminated cryptococcal infection in rheumatoid arthritis treated with methotrexate and infliximab. J. Rheumatol.29, 1561–1563 (2002).
   PubMed Web of Science ®Google Scholar
• Wallis RS, Broder MS, Wong JY, Hanson ME, Beenhouwer DO. Granulomatous infectious diseases associated with tumor necrosis factor antagonists. Clin. Infect. Dis.38, 1261–1265 (2004).
   PubMed Web of Science ®Google Scholar
• Wallis RS, Broder M, Wong J, Beenhouwer D. Granulomatous infections due to tumor necrosis factor blockade: correction. Clin. Infect. Dis.39, 1254–1255 (2004).
   PubMed Web of Science ®Google Scholar
• Bergstrom L, Yocum DE, Ampel NM et al. Increased risk of coccidioidomycosis in patients treated with tumor necrosis factor-α antagonists. Arthritis Rheum.50, 1959–1966 (2004).
   PubMed Web of Science ®Google Scholar
• Warris A, Bjorneklett A, Gaustad P. Invasive pulmonary aspergillosis associated with infliximab therapy. N. Engl. J. Med.344, 1099–1100 (2001).
   PubMed Web of Science ®Google Scholar
• Gluck T, Linde HJ, Scholmerich J, Muller-Ladner U, Fiehn C, Bohland P. Anti-tumor necrosis factor therapy and Listeria monocytogenes infection: report of two cases. Arthritis Rheum.46, 2255–2257 (2002).
   PubMed Web of Science ®Google Scholar
• Kamath BM, Mamula P, Baldassano RN, Markowitz JE. Listeria meningitis after treatment with infliximab. J. Pediatr. Gastroenterol. Nutr.34, 410–412 (2002).
   PubMed Web of Science ®Google Scholar
• Slifman NR, Gershon SK, Lee JH, Edwards ET, Braun MM. Listeria monocytogenes infection as a complication of treatment with tumor necrosis factor-α-neutralizing agents. Arthritis Rheum.48, 319–324 (2003).
   PubMed Web of Science ®Google Scholar
• Stephens MC, Shepanski MA, Mamula P, Markowitz JE, Brown KA, Baldassano RN. Safety and steroid-sparing experience using infliximab for Crohn’s disease at a pediatric inflammatory bowel disease center. Am. J. Gastroenterol.98, 104–111 (2003).
   PubMed Web of Science ®Google Scholar
• Keane J, Gershon S, Wise RP et al. Tuberculosis associated with infliximab, a tumor necrosis factor-α-neutralizing agent. N. Engl. J. Med.345, 1098–1104 (2001).
   PubMed Web of Science ®Google Scholar
• Walsh N. Herpes reactivation observed with TNF inhibitors. Family Practice News23–24 (2007).
   Google Scholar
• Sichletidis L, Settas L, Spyratos D, Chloros D, Patakas D. Tuberculosis in patients receiving anti-TNF agents despite chemoprophylaxis. Int. J. Tuberc. Lung Dis.10(10), 1127–1132 (2006).
   PubMed Web of Science ®Google Scholar
• Rychly DJ, Dipro JT. Infections associated with tumor necrosis-α antagonist. Pharmacology25(9), 1181–1192 (2005).
   Google Scholar
• Nash PT, Florin TH. Tumor necrosis factor inhibitor. Med. J. Aust.183(4), 203–208 (2005).
   Google Scholar
• Bongartz T, Sutton A, Sweeting M, Buchan I, Matteson E, Montori V. Anti-TNF antibody therapy in rheumatoid arthritis and the risk of serious infections and maligancies. JAMA295, 2275–2285 (2006).
   PubMed Web of Science ®Google Scholar
• Trent J, Kerdel FA. Using biologic agents off-label. Skin Aging13(11), 48–52 (2005).
   Google Scholar
• Burgess IF. Human lice and their management. Adv. Parasitol.36, 271–342 (1995).
   PubMedGoogle Scholar